The combination of PI3K/AKT/mTOR and CDK4/6 inhibitors has been studied in preclinical models18,20,49 and is still under research in clinical trials in patients with advanced breast cancer (NCT02389842), lung cancer and other cancers (NCT03065062). Here, CDK4 is linked to lung carcinoma.